Lowering Drug Costs for American Families Act
- Sponsor
- Rep. Pallone, Frank [D-NJ-6]
- Committees
- Education and Workforce Committee (primary)
- Last action
- Nov 20, 2025
Bottom line
The bill aims to reduce prescription drug costs for American families by expanding federal price controls and capping out-of-pocket expenses across Medicare and commercial insurance markets.
What it actually does
This bill significantly expands federal intervention in prescription drug pricing and cost-sharing. It increases the number of drugs subject to Medicare price negotiation, extends these negotiated prices to the commercial market, applies Medicare drug inflation rebates to commercial sales, and establishes new out-of-pocket limits for prescription drugs, including a $2,000 annual cap and a $35/month cap for insulin, under private health insurance.
Proponents argue
Supporters argue that the bill will make life-saving medications more affordable and accessible for millions of Americans by reining in exorbitant drug prices and protecting consumers from high out-of-pocket costs. They contend it will reduce the financial burden on families, prevent medical debt, and improve health outcomes by ensuring patients can afford necessary treatments.
Opponents contend
Opponents argue that expanding government price controls to the commercial market will stifle pharmaceutical innovation, reduce research and development into new cures, and ultimately limit patient access to new drugs. They also raise concerns about potential market distortions, increased administrative burdens on health plans, and the possibility of higher premiums for other healthcare services.
The bill is moderately complex due to its reliance on existing statutes and detailed amendments, requiring a careful read. The time given for public and legislative review would be critical for stakeholders to fully understand its implications.
Section 101(a)
Expansion of Negotiated Drugs
This provision amends the Social Security Act to increase the number of drugs subject to Medicare price negotiation from 20 to 50. This means that a significantly larger pool of high-cost prescription drugs will be eligible for price negotiation by the federal government, potentially leading to lower prices for these medications.
Supporters argue
Supporters argue this will significantly increase savings for Medicare and beneficiaries, bringing down costs for more essential medications and expanding access to affordable treatments.
Critics contend
Critics contend that increasing the number of negotiated drugs will further reduce pharmaceutical research and development incentives, potentially leading to fewer new treatments being developed in the future.
Tradeoffs
The provision balances the immediate goal of greater cost savings for patients and the Medicare program against potential long-term impacts on pharmaceutical innovation and the development of new drugs.
Section 101(b)-(e)
Extending Negotiated Prices to Commercial Plans
This section amends multiple statutes (Social Security Act, Public Health Service Act, ERISA, and the Internal Revenue Code) to allow group health plans and health insurance issuers in the commercial market to voluntarily participate in the Medicare Drug Price Negotiation Program. If they participate, they must apply the maximum fair price (negotiated by Medicare) to their cost-sharing calculations for selected drugs, and their cost-sharing cannot exceed this maximum fair price. Plans can opt out but must publicly disclose their non-participation.
Section 102
International Price Index for Negotiation
This provision amends the Social Security Act to require the Secretary to consider the average international market price for a drug when negotiating prices. This price would be calculated as the net average, volume-weighted price from sales in Australia, Canada, France, Germany, Japan, and the United Kingdom. This new consideration applies to negotiations for initial price applicability years beginning on or after January 1, 2028.
Section 103
Reversal of Prior Program Changes
This section repeals Section 71203 of Public Law 119-21, effectively restoring the provisions of law amended by that section to their state before its enactment. Without the text of Public Law 119-21, the precise nature of the changes being reversed is not detailed in this bill, but it indicates a legislative intent to revert certain aspects of the drug price negotiation program to an earlier version.
Section 201
Commercial Market Inflation Rebates
This section extends the Medicare drug inflation rebate program to drugs furnished in the commercial market. This means that if the price of a drug covered by private insurance rises faster than inflation, the manufacturer would be required to pay a rebate. The provision details how to calculate these rebates for both Part B drugs (administered by providers) and Part D drugs (retail pharmacy) in the commercial market, adjusting for units and existing rebates.
Section 301
Commercial Out-of-Pocket Caps
This section establishes new annual out-of-pocket limits for prescription drugs under private health insurance (group and individual market) starting in 2027. For self-only coverage, the limit is $2,000, and for other coverage, it's twice that amount, adjusted annually for inflation. It also sets overall out-of-pocket limits for all annual cost-sharing, aligning with Affordable Care Act (ACA) limits but adjusted for inflation.
Section 302
Insulin Cost-Sharing Cap
For plan years beginning on or after January 1, 2027, this section requires group health plans and health insurance issuers to cover selected insulin products without applying a deductible. Additionally, cost-sharing for these products must be limited to the lesser of $35 per 30-day supply or 25% of the negotiated price (net of concessions). This cap applies to both in-network and out-of-network providers, though plans can impose higher cost-sharing for out-of-network services.
Specifies that for drugs furnished or administered by a hospital, physician, or other provider, the provisions of the drug price negotiation program apply to commercial plans and enrollees in the same manner as they apply to Medicare.
Section 101(e)(1)(B) and similar sections
Why it matters:This is standard legislative practice when extending existing regulatory frameworks to new populations, ensuring consistent application of rules. However, the full implications require understanding the referenced Medicare rules, which are not detailed in this bill.
Case for: Proponents argue this ensures consistent application of negotiated prices regardless of how the drug is administered, preventing loopholes and ensuring that patients benefit from lower prices in all care settings.
Case against: Critics contend this increases the administrative complexity for commercial plans and providers, who must now align with Medicare's administrative procedures for these drugs, potentially leading to implementation challenges.
Estimated impact: Expands the scope of Medicare's administrative requirements to a significant portion of the commercial market for certain drugs, affecting how providers and plans process claims and apply prices.
Beginning with plan year 2026, units of Part D rebatable drugs for which the manufacturer provides a discount under the 340B program are excluded from the total number of units used to calculate inflation rebates.
Section 201(b)(1)(B)(iii)
Why it matters:This is a technical adjustment aimed at preventing manufacturers from being penalized twice for price concessions (once for 340B discounts, once for inflation rebates), ensuring the rebate calculation accurately reflects market prices. It's a standard legislative refinement.
Case for: Proponents argue this prevents double-counting of discounts and ensures fairness to manufacturers, which can help maintain the stability of both the 340B program and the inflation rebate program.
Case against: Some might argue that 340B discounts are separate and inflation rebates should apply broadly to all units, but this is generally considered a technical correction to avoid unintended consequences.
Estimated impact: Clarifies the interaction between two major drug pricing programs, potentially reducing administrative burden for manufacturers and ensuring fair rebate calculations, with a minor impact on overall rebate amounts.
States that the amendments made by Section 301 (establishing out-of-pocket limits for prescription drugs under private health insurance) shall apply with respect to plan years beginning on or after January 1, 2027.
Section 301(e)
Why it matters:Specifying effective dates is standard legislative practice. The delayed effective date is a practical necessity to allow health plans and issuers sufficient time to adjust their benefit designs, systems, and contracts to comply with the new out-of-pocket limits.
Case for: Proponents argue that the delayed effective date provides necessary lead time for the complex operational changes required by health plans and insurers, ensuring a smoother transition and implementation.
Case against: Critics might argue that delaying the effective date postpones crucial financial relief for consumers who are currently facing high drug costs, extending their financial burden unnecessarily.
Estimated impact: Delays the implementation of new out-of-pocket caps for private insurance by over a year from the bill's introduction date, impacting when consumers will see these protections.